Pain Management

A recent experience made me realize that pain management is changing.

Research finds patients are fearful of decreasing or stopping medications.

It may have a funny name, but dormant butt syndrome causes some patients to experience knee, back, or hip pain.

The drug 16-8 was able to stop abdominal pain from pancreas inflammation in mice.

How long an individual can endure pain may provide a clue into the size of his or her social contacts.

Research may lead to new therapeutic strategies for treating allodynia.

Chronic pain and hormone replacement among the most frequently used compounded medications.

Opioid abuse has been garnering more attention as the public and private sectors take steps to address the increasing number of opioid-related overdose deaths.

Failing to properly dispose of unfinished medications can have dire consequences.

Discovery may lead to pharmaceutical compounds that target protein structure.

After total knee replacement surgery, patients younger than 45 years and those aged 75 years or older seem to report more pain and less activity than their peers.

Patients with chronic obstructive pulmonary disease have reductions in their brains' gray matter related to the processing of dyspnea, fear, and sensitivity to painful stimuli.

Neuropathic pain is a chronic nerve pain that can significantly impair a patient's functioning and quality of life.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses the role pharmacists can play in helping physicians interpret urine screens.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses the problems related to inappropriate equianalgesic conversions when performing opioid rotations.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses and debunks the myths and hysteria surrounding the use of opioid therapy in treating non-cancer pain.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses strategies pharmacists can employ to enhance the safe use of chronic opioid therapy.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses whether or not allowing pharmacists to dispense naloxone without a prescription can help reduce fatal outcomes.

The FDA has approved Belbuca buccal film for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The Centers for Disease Control and Prevention released final guidelines today that provide recommendations for prescribers with a goal of improved care and safety of patients being treated for chronic pain.

The risks of undertreating pain in the pediatric population are significant.

The FDA has accepted Egalet Corporation's new drug application for morphine sulfate extended-release tablets (Arymo ER).

To better understand the risks of Essure, a permanent method of birth control, the FDA has called for a new mandatory clinical study to look at its risks.

Iroko Pharmaceuticals' meloxicam (Vivlodex) capsules, designed to treat osteoarthritis pain, are now available by prescription at pharmacies across the United States.

A Super Bowl 50 commercial may be encouraging patients to seek help for their constipation.

Although clinicians are able to identify the causes of neuropathic pain, the mechanism behind its treatment is more difficult to distinguish.

The American College of Medical Toxicology recently issued position statements on opioid prescribing.

More than 100 million Americans experience pain each day, and it has been associated with a $500 billion economic burden in the United States.

Whether transient, spontaneous, or a triggered exacerbation of adequately controlled baseline aches, breakthrough pain is a difficult symptom for providers to gauge.

Data from large survey reports suggest that more than 80% of Americans who undergo surgery experience some level of postsurgical pain.